loader2
Partner With Us NRI

Company details

1,514.90
1,539.00
1,433.05
1,917.00
6M Return -13.00%
1Y Return 1.58%
Mkt Cap.(Cr) 25,947.07
Volume 5,907
Div Yield 5.99%
OI
-
OI Chg %
-
Volume 5,907

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 2,662.96 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 18,658.80 -44,480.27
LAST 3M 70,889.04 -85,599.64
LAST 6M 138,573.25 -221,926.67
LAST 12M 230,551.63 -248,467.70

Information

  • About Company
  • Company Info
  • Listing Info
15.12
75%
157.1937
89.25%
81.85%
Description
  • GlaxoSmithKline Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 25,676.02 crores, it is incorporated in the year 1924. It has reported consolidated sales of Rs. 789.99 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500660, and also listed on the National Stock Exchange (NSE) with the code GLAXO.

    GlaxoSmithKline Pharmaceuticals is one of the leading manufacturers of pharmaceuticals and vaccines in India. GSK entered the Indian market under the name of H J Foster & Co Ltd. The company generated 76% of its revenue from the selling and distribution of pharmaceuticals while the vaccine segment generated 24% of its revenue. 5 of the brands marketed by GSK feature in the India Pharmaceutical Market. These brands are (i) Augmentin, (ii) Betnovate, (iii) Calpol, (iv) Ceftum, and (v) Synflorix. GSK has a developed a team of over 5,000 employees spread across the country. GSK has also established two global Research & Development centers in the country. The promoters of the company own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 1.61% of the stake, Domestic Institutional Investors (DII) own 10.92%, and others (such as public & retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 773.46 crores, which has increased by approximately 19.24 % from Rs. 648.65 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 120.4 crores, which has improved sharply and increased by nearly 8.51% from a net profit of Rs. 110.96 crores in June 2020. In June 2021, the reported operating profit was at Rs. 645.05 crores, which is increased by 10.95% as compared to an operating profit of Rs. 581.39 crores for the quarter ending in June 2020. From an EPS of Rs. 6.55 in June 2020, the EPS of Glaxosmithkline Pharmaceuticals Ltd has improved and reached an EPS of Rs. 7.11 per share in June 2021. GLAXO's stock closed at Rs. 1,515.65 on 27th August’2021 (NSE). GlaxoSmithKline Pharmaceuticals Ltd has returned 3.77% in the last six months and returned 5.18% negatively in the previous year.

Read More

Registered Address

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24959595
Email : askus:gsk.com
Website : http://www.gsk-india.com

Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500660
NSE Code : GLAXO
Book Closure Date (Month) :
BSE Group : A
ISIN : INE159A01016

ICICIdirect Glaxosmithkline Pharmaceuticals Ltd FAQ

You can buy Glaxosmithkline Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glaxosmithkline Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jul 04, 2022 04:01 PM the closing price of Glaxosmithkline Pharmaceuticals Ltd was ₹ 1,531.65.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jul 04, 2022 04:01 PM, the market cap of Glaxosmithkline Pharmaceuticals Ltd stood at ₹ 25,947.07.
The latest PE ratio of Glaxosmithkline Pharmaceuticals Ltd as of Jul 04, 2022 04:01 PM is 15.12
The latest PB ratio of Glaxosmithkline Pharmaceuticals Ltd as of Jul 04, 2022 04:01 PM is 0.10
The 52-week high of Glaxosmithkline Pharmaceuticals Ltd is ₹ 1,917.00 while the 52-week low is ₹ 1,433.05 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE